About Nohla Therapeutics
Nohla Therapeutics is a company based in Seattle (United States) founded in 2015 by Colleen Delaney. It operates as a B2B. Nohla Therapeutics has raised $120.5 million across 4 funding rounds from investors including Fidelity Investments, ARE and Celgene. The company has 48 employees. Nohla Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Seattle, United States
- Employees 48
- Founders Colleen Delaney
- SectorsHealthcare
- Website nohlatherapeutics.com
- Social X
- Legal Name Nohla Therapeutics Inc.
- Total Equity Funding$120.5M (USD)
in 4 rounds
- Latest Funding Round$11M (USD), Series B
Jul 2018
- InvestorsFidelity Investments
& 9 more
- Employee Count48
Funding Insights of Nohla Therapeutics
Nohla Therapeutics has successfully raised a total of $120.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $11 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120.5M
- Total Rounds 4
- Last Round Series B — $11M
- First Round $21M
(Dec 2015)
- Investors Count 10
All 4 funding rounds of Nohla Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2018 | $11M | Series B | – | UTEC, Schroders Capital | – |
| May 2018 | $45M | Series B | – | Fidelity Investments | |
| Nov 2017 | $43.5M | Series A | – | Arch Venture Partners | |
| Dec 2015 | $21M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in Nohla Therapeutics
Nohla Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and Early stage VC firm investing in Japan | – | ut-ec.co.jp | Tokyo, Japan | |
Private equity & venture capital firm | – | premierpartners.co.kr | Seoul, South Korea | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital fund backed incubator focused on the healthcare startups | – | 5amventures.com | San Francisco, United States | |
Early stage investments focused VC firm | – | acks.com | - | |
Manages private equity, real estate, and infrastructure investments for various investors. | 1997 | schroderscapital.com | London, United Kingdom | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
- | – | safety-flooring.com.au | - |
Investor details for Nohla Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nohla Therapeutics
1 people are tracked at Nohla Therapeutics (1 in leadership); the tracked headcount is 48.
| Name | Role | Group |
|---|---|---|
Colleen Delaney | ex-Co-Founder | Leadership |
Complete people profiles for Nohla Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nohla Therapeutics
3 dated milestones of Nohla Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Nohla Therapeutics is founded.
- Funding First funding round of $21.0M.
- Funding Latest funding round, Series B, of $11.0M.
Competitors of Nohla Therapeutics
Nohla Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Nohla Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nohla Therapeutics
The website of Nohla Therapeutics (nohlatherapeutics.com) receives about 680.7K visits a month.
- Monthly visits680.7K
▼ 6.7% vs previous month
Websites whose visitors overlap most with Nohla Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Nohla Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Nohla Therapeutics
Complete news archive for Nohla Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Nohla Therapeutics
10 companies that operate in the same segment as Nohla Therapeutics (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nohla Therapeutics
Nohla Therapeutics was founded in 2015.
Nohla Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Nohla Therapeutics is a funded company, having raised a total of $120.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $21M, raised on Dec 2015.
Nohla Therapeutics has 48 employees.
Nohla Therapeutics, founded in 2015 in Seattle, United States, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and stem-cell treatments. Develops stem-cell transplant solutions using umbilical cord blood as an alternative to bone-marrow transplants. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Nohla Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Nohla Therapeutics has 10 investors. Key investors include Fidelity Investments, ARE, Celgene, Arch Venture Partners, and UT-EC Japan.
Nohla Therapeutics operates through Nohla Therapeutics Inc..
The website of Nohla Therapeutics receives about 681 thousand visits a month.